ICER’s Revised Value Assessment Framework for 2017–2019: A Critique Peter J. NeumannJoshua T. Cohen Commentary 08 August 2017 Pages: 977 - 980
Availability and Pricing New Medicines in Ireland: Reflections and Reform Paul K. Gorecki Current Opinion 05 July 2017 Pages: 981 - 987
Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment Syed SallehPraveen ThokalaSimon Dixon Systematic Review 03 July 2017 Pages: 989 - 1006
Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology Mohamed El AliliJohanna M. van DongenJudith E. Bosmans Systematic Review Open access 03 July 2017 Pages: 1007 - 1033
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Nigel FleemanAdrian BagustMiranda Payne Review Article 18 March 2017 Pages: 1035 - 1046
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis Steven SimoensIra JacobsLesley G. Shane Review Article Open access 28 June 2017 Pages: 1047 - 1062
Performance-Based Risk-Sharing Arrangements: An Updated International Review Josh J. CarlsonShuxian ChenLouis P. Garrison Jr Review Article 10 July 2017 Pages: 1063 - 1072
Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis Eric JutkowitzFernando Alarid-EscuderoHawre Jalal Original Research Article 19 June 2017 Pages: 1073 - 1085
Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008–2012 Abaigeal D. JacksonAndrew L. JacksonEdward McKone Original Research Article 11 July 2017 Pages: 1087 - 1101
Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code Jörgen MöllerSarah DavisJ. Jaime Caro Original Research Article 01 July 2017 Pages: 1103 - 1109